AzTrials
AzTrials

OsteoporosisPhase 1ChymosinNCT01370941

The Effect of Chymosin on the Intestinal Absorption of Calcium

A Phase 1 study testing Drug A Chymosin in people with Osteoporosis and Osteopenia, run by University of Aarhus at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An adequate calcium intake is important for bone turnover and the risk of developing osteoporosis. Yet many studies have documented that supplementation with calcium tablets are often associated with a poor compliance, therefore it is important to explore ways to better calcium influx. Read more about this study

Who is it for?
Ages 25 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Osteoporosis, Osteopenia
What is being tested?
Drug A Chymosin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
125 participants
Where
1 siteDenmark
Study dates
Apr 2011to Mar 2012
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • A stable daily intake of calcium on estimated 500-1200 mg, of which dairy products are minimum 500 mg
  • Speak and read Danish.
  • Written consent after verbal and written information

Who cannot join

  • Known lactose intolerance / milk allergy
  • Use of calcium supplements in tablet or powder
  • Intake of vitamin D supplements exceeding 10 micro grams/day
  • A habitual dietary calcium intake exceeding 1200 mg/day
  • Impaired renal function (plasma creatinine >150 micro mol/L)
  • Impaired liver function (plasma ALT >200 U/L, alkaline phosphatase >400 U/L).
Show all 14Show fewer
  • Previous or present malignancies(including metastases).
  • sarcoidosis or second granulomatous disease which has caused hypercalcaemia
  • Pregnancy, breastfeeding
  • Postmenopausal women
  • Disease or treatment with drugs known to affect calcium homeostasis, including diuretics, osteoporosis agents, lithium, steroids, etc..
  • Pledged due to chronic alcoholism.
  • Severe medical or social problems which makes it unlikely that the participant can complete the survey
  • Lack of willingness / desire to participate

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Ward 900, Osteporosis clinic, Aarhus University Hospital, THG

    Aarhus, Jutland, 8000

Other trials in Denmark

About this study

Official title: The Effect of Chymosin on the Intestinal Absorption of Calcium: A Randomized Controlled Cross-over Trial

An adequate calcium intake is important for bone turnover and the risk of developing osteoporosis. Yet many studies have documented that supplementation with calcium tablets are often associated with a poor compliance, therefore it is important to explore ways to better calcium influx.

Calcium consumed through dairy products must first be cleaved from the molecules which it is bound to before it can be absorbed. Chymosin is an enzyme which cleaves the protein binding between some amino acids in κ-casein. The reaction occurs after ingestion of milk and causes a process whereby the time the milk is staying gastrointestinal tract is extended, this can lead to enhanced uptake of calcium.

Read more

When the body's calcium balance is in equilibrium excretion in urine (24 h) in roughly the size of the intake, whereby a measurement of circadian urine excretion of calcium can determine the amount of calcium absorbed from the intestine.

The investigators want to clarify whether the addition of chymosin to milk increases calcium absorption. Secondary to explore issues of significance for this effect, including vitamin D status and amount of daily calcium intake and whether a change in calcium absorption has immediate effects on bone turnover (measured as plasma osteocalcin, bone specific alkaline phosphatase (BSAP), and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio) and on the parathyroid function (measured as PTH). Finally we will explore relations between bone mineral density (BMD) and the measured parameters (in terms of P-PTH, P-25OHD, P-1,25(OH)2D, P-osteocalcin, P-BSAP, and U-NTx/Cr).

Read the detailed description

Background:

Osteoporosis is a frequent disease. Allegedly, more than 500,000 Danes are diagnosed with osteoporosis and, in consequence, seems every year more than 20,000 fractures. A number of factors are known to increase the risk of osteoporosis, including a low daily intake of calcium.

Several clinical trials with calcium supplements for adults (with or without simultaneous supplementation of vitamin D) have shown an increase in bone mineral density (Bone Mineral Density, BMD) and reduction the risk of fractures. Similarly, several studies have shown that high milk intake during childhood and adolescence may increase bone mass and reduce the risk of fractures later in life.

Since an adequate calcium intake is important for bone turnover and the risk of developing osteoporosis, it is important to explore ways to better calcium influx. Several studies have documented that supplementation with calcium tablets are often associated with a poor compliance - people do not remember to take the tablets. It is therefore desirable to find methods that can increase the intake of the amount of calcium which occurs naturally in the diet.

Calcium consumed through dairy products must first be cleaved from the molecules which it is bound to before it can be absorbed. Various methods have been tried to optimizing the amount of calcium absorbed from dairy products, including the addition of so called fructo-oligosaccharides (FOSS) and casein phosphopeptides (CPPs).

Chymosin is an enzyme which cleaves the protein binding between some amino acids in κ-casein. The reaction occurs after ingestion of milk and causes a process whereby the time the milk is staying gastrointestinal tract is extended, this can lead to enhanced uptake of calcium. When the body's calcium balance is in balance the excretion in urine (24 h)is in roughly the size as the intake. Therefore a measurement of circadian urine excretion of calcium can determine the amount of calcium absorbed from the intestine.

Purpose and hypothesis:

Primarily the study intends to clarify whether the addition of chymosin to milk increases the intestinal calcium absorption. Secondary to explore issues of significance for this effect, including vitamin D status and amount of daily calcium intake, and whether a change in calcium absorption has immediate effects on bone turnover (measured as plasma osteocalcin, plasma bone specific alkaline phosphatase, and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio) and on the parathyroid function (measured as PTH). Finally we will explore relations between bone mineral density (BMD) and the measured parameters (in terms of P-PTH, P-25OHD, P-1,25(OH)2D, P-osteocalcin, P-BSAP, and U-NTx/Cr).

Design:

The study is conducted as a randomized double-blinded controlled cross-over trial in which 125 healthy subjects will be asked to drink a glass of milk with or without added chymosin at two occasions. The two time two test days will be separated by 10-18 days. Neither study participants nor the staff conducting the investigation (investigator) will while the trial will be conducted know on which day of the trial which milk contains chymosin (double-blinded). About chymosin added to milk on the first or second test day will be determined by lot (randomized study).

Study Population:

Healthy participants in the agegroup of 25-40 years old are recruited. From the central personal register (CPR register) a list of young people living in the Aarhus area is drawn up, followed by sending out a direct letter asking for participation in the study. At the same time a questionnaire will clarify whether participation is possible, i.e. whether the criteria for participation in the survey are meet.

Being tested
Drug A Chymosin, Drug B: Placebo
Keywords
Chymosin, 24H urine calcium excretion, Calcium absorption, Intestinal Absorption of Calcium
Medical subject headings
Osteoporosis, Bone Diseases, Metabolic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Drug A ChymosinDietary supplement

    Also called Chy-max plus IMCU200

    Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.

  • Drug B: PlaceboDietary supplement

    Also called Water

    B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.

Study groups in NCT01370941
Study groupRoleWhat they receive
Drug A: ChymosinActive comparatorA: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
Receives: Dietary Supplement: Drug A Chymosin
Drug B: PlaceboPlacebo comparatorB: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
Receives: Dietary Supplement: Drug B: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine

    The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine

    Measured: Two time two days over an eighteen days period

Secondary outcomes (3)
  1. The effect of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels on the amount of calcium absorbed and the potential impact of chymosin

    Vitamin D: The importance of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D on the amount of calcium absorbed and the potential impact of chymosin.

    Measured: Two time two days over an eighteen days period

  2. The immediate biological effects of the intervention on P-PTH, and bone turnover (P-osteocalcin, P-BSAP, U-NTX)

    The immediate biological effects of the intervention on parathyroid function (PTH) and bone turnover (P-osteocalcin, plasma bone specific alkaline phosphatase, and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio).

    Measured: Two time two days over an eighteen days period

  3. Relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr)

    To explore relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr).

    Measured: Will be measured one time at one of the two time two days over an eighteen days period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2011 (estimated)
  2. Study startApr 2011
  3. Primary completionMar 2012
  4. Study completionMar 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
125 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01370941
Sponsor's protocol ID
Chymo-01
Other IDs
20110007
Acronym
Chymosin
Status last verified
Mar 2012
First submitted
27 Apr 2011
Last updated
21 Mar 2012
Results posted
No
Data monitoring committee
No

Publications

  • Moller UK, Jensen LT, Mosekilde L, Rejnmark L. Effects of adding chymosin to milk on calcium homeostasis: a randomized, double-blind, cross-over study. Calcif Tissue Int. 2015 Feb;96(2):105-12. doi: 10.1007/s00223-014-9942-8. Epub 2014 Dec 18.

    PubMed 25515208

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Drug A Chymosin in people with Osteoporosis and Osteopenia, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Mar 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine (time frame: Two time two days over an eighteen days period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01370941, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in